top of page

A novel intraocular implant that preserves the capsular form and intracapsular space. An unmet challenge in replacement of the natural lens by an IOL, preventing optimisation of the visual outcome! 

PCO, refractive surprise, Pseudophakic Dysphotopsia, IOL decentration and instability, anterior capsule phimosis, and PVD are the main associated complications.

PCO and Nd:YAG Capsulotomy

Up to 50% of patients may develop PCO within 2 - 5 years. Up to 37% may undergo Nd:YAG laser capsulotomy. ¹⁻⁸

 

Complication in up to 19.8% of Nd:YAG capsulotomies (IOL pitting/dislocation, cystoid macular edema, increased IOP, retinal detachment) ³, ⁹⁻¹⁴

 

The increased patient’s demands and popularity of premium IOLs has increased the importance of PCO prevention.¹⁶

Refractive Error & Surprise

Depending on the IOL, up to 47.6% of patients may require glasses due to postoperative refractive surprise.²⁰

64% of patients implanted with a multifocal IOL are suffering from residual refractive error.²⁰

Loss of intracapsular volume and capsular fibrotic effects are complicating the replacement of an IOL.

Additional Complications

49% of patients will experience some aspect of dysphotopsia.²¹

0.21% to 1.40% incidence rate of capsular bag phimosis.²²

0.2% to 3% incidence rate of IOL dislocation.¹⁷⁻¹⁹

27.3% complete PVD with a 7-fold higher hazard risk ratio for progression to complete PVD.²³

A ground-breaking solution that defines a new era in cataract and refractive lens exchange surgery!

Shaped like a torus with a perfect balance of stability and flexibility, fixOflex™ is a medical implantable endocapsular device used during surgery prior to IOL implantation. It was designed to both fix the implanted IOL in its place and flex the empty capsule of the human crystalline lens to preserve its natural 3-D state and intracapsular volume. By doing so, it provides a platform that offers multitude of benefits.

2024
Initiation of official pediatric study
2012
Initial conception of the idea
2023
Completion of official clinical trials 
2017
 US Patent application
2019
Initiation of official clinical trials
2016
Initial peer reviewed publication
2020
US Patent application granted 
2018
Establishment of Eye PCR B and worldwide patent application
2023
Worldwide patent application granted in various countries
Expecting CE Mark by mid 2024
2016
Initial peer reviewed publication
2018
Establishment of EYE PCR BV and worldwide patent application
2020
USA patent application granted
2023
Completion of official clinical trials
2012
Initial conception of the idea
2017
US Patent application
2019
Initiation of official clinical trials 
2023
Worldwide patent application granted in various countries
2024
Initiation of official pediatric study
Expecting CE Mark by mid 2024

Eye PCR is pioneering a new chapter in eye care.

Healio presents the fixOflex speak of Prof. Pallikaris

Prof. Pallikaris describes how to utlise the fixOflex during IOL implantation and discusses his 2022 ESCRS presentation.

Prof. Pallikaris’ presenting EYE PCR and fixOflex on iNovation day at ESCRS Milan

Eyewire prologuing EYE PCR’ s presentation on fixOflex at the ESCRS meeting in Milan

Dr. Santaro Noguchi presented our product and results at the 45th Annual Meeting of the Japanese Society of Ophthalmic Surgery.

We are proud to announce that we have successfully integrated 120 cases in the clinical study of Alexandria site.

Initiation of the additional clinical trial at the University of Crete

Establishment of Eye PCR

Embrace the future in IOL implantation with fixOflex by staying connected through our newsletter

bottom of page